177 related articles for article (PubMed ID: 38055239)
1. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
[TBL] [Abstract][Full Text] [Related]
2. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
[TBL] [Abstract][Full Text] [Related]
4. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.
Singla S; Putman M; Liew J; Gordon K
Lancet Rheumatol; 2023 Apr; 5(4):e200-e207. PubMed ID: 38251522
[TBL] [Abstract][Full Text] [Related]
5. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
6. Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics.
Al-Janabi A; Eyre S; Foulkes AC; Khan AR; Dand N; Burova E; DeSilva B; Makrygeorgou A; Davies E; Smith CH; Griffiths CEM; Morris AP; Warren RB;
J Invest Dermatol; 2023 Aug; 143(8):1470-1478.e1. PubMed ID: 36804406
[TBL] [Abstract][Full Text] [Related]
7. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis.
Balakirski G; Burmann SN; Hofmann SC; Kreuter A
J Dermatolog Treat; 2023 Dec; 34(1):2258240. PubMed ID: 37705378
[No Abstract] [Full Text] [Related]
9. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.
Al-Janabi A; Foulkes AC; Mason K; Smith CH; Griffiths CEM; Warren RB
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1440-1448. PubMed ID: 31997406
[TBL] [Abstract][Full Text] [Related]
10. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.
Ding L; Chen C; Yang Y; Zhang X
Front Immunol; 2024; 15():1349636. PubMed ID: 38384460
[TBL] [Abstract][Full Text] [Related]
11. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.
Al-Janabi A; Martin P; Khan AR; Foulkes AC; Smith CH; Griffiths CEM; Morris AP; Eyre S; Warren RB;
J Allergy Clin Immunol; 2023 Nov; 152(5):1237-1246. PubMed ID: 37536512
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
[TBL] [Abstract][Full Text] [Related]
13. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN; Ashcroft DM; Evans I; McElhone K; Lunt M; Smith CH; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
Br J Dermatol; 2019 Feb; 180(2):329-337. PubMed ID: 30070708
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
Bataille P; Layese R; Claudepierre P; Paris N; Dubiel J; Amiot A; Sbidian E;
Br J Dermatol; 2022 Nov; 187(5):676-683. PubMed ID: 35770735
[TBL] [Abstract][Full Text] [Related]
15. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
16. Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN; Smith CH; Ashcroft DM; Lunt M; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
J Invest Dermatol; 2018 Mar; 138(3):534-541. PubMed ID: 29054603
[TBL] [Abstract][Full Text] [Related]
17. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
[TBL] [Abstract][Full Text] [Related]
19. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
20. Incidence, Risk Factors, and Consequences of Human Alphaherpesvirus Infections in Patients With Psoriasis Who Initiate Methotrexate or Biologic Agents.
Rezahosseini O; Liljendahl MS; Loft N; Møller DL; Harboe ZB; Rasmussen MK; Ajgeiy KK; Egeberg A; Skov L; Nielsen SD
J Infect Dis; 2022 Nov; 226(9):1510-1518. PubMed ID: 36097341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
